Suzuki Atsushi
   Department   School of Medicine(Tokyo Women's Medical University Hospital), School of Medicine
   Position   Assistant Professor
Language English
Title Clinical Features of Japanese Hypertrophic Cardiomyopathy Patients with Stroke and Systemic Embolic Events
Conference The 79th Annual Scientific Meeting of the Japanese Circulation Society
Promoters Japanese Circulation Society
Conference Type Nationwide Conferences
Presentation Type Speech
Lecture Type General
Publisher and common publisher◎HARUKI Shintaro, MINAMI Yuichiro, SUZUKI Atsushi, SUZUKI Tsuyoshi, SHIGA Tsuyoshi, HAGIWARA Nobuhisa
Date 2015/04/26
(city and name of the country)
Osaka, JAPAN
Society abstract PROGRAM JCS 2015 616
Summary Background: Although stroke and systemic embolic events are known to occur as complications of hypertrophic cardiomyopathy (HCM), few data are available regarding the occurrence and profile of these events from Japan. We investigated the frequency and clinical features of HCM patients with these complications from a tertiary referral cohort in Japan. Methods and Results: Of the 550 HCM patients (follow-up: 10.9±7.4 years), 62 patients (11.3%) experienced embolic events including 57 patents with stroke, and age at first event ranged from 23 to 83 (mean 60.0±11.8) years. Although patients with events had larger left atrium, there were no significant differences with respect to age at diagnosis, gender, family history of sudden death, syncope, left ventricular obstruction and wall thickness between the patients with and without events. Of the 149 patients with documented atrial fibrillation (AF), 73 patients received anticoagulation with warfarin. The incidence of embolic events among non-anticoagulated patients with AF was higher than anticoagulated patients with AF (21.1% vs. 13.7%). At the time of the initial event, however, AF was not previously documented in 36 (58.1%) of 62 patients with events. Conclusion: Stroke and systemic embolic events showed an incidence of 1.0%/year in Japanese HCM patients. Although anticoagulation might be effective in reducing the events in patients with AF, prevention of events in patients without AF remains a clinical challenge.